CD276

I'm your host, Kemi Abujimi.

Today's episode features expert perspectives on the evolving role of B7H3-directed antibody drop conjugates in the extensive-state small-cell lung cancer treatment landscape.

This episode is part of a larger educational program titled From Biomarker to Bedside, B7H3-Directed Antibody Drug Conjugates in the Evolving Extensive State Small Cell Lung Cancer Treatment Landscape.

This podcast features Dr. Charles Riddin, Cancer Center Director at the Memorial Sloan Kettering Cancer Center in New York, and Dr.

Mark Sosinski, Executive Medical Director at the Advent Health Cancer Institute in Orlando, Florida.

Thank you so much, Dr. Rudin and Dr. Sosinski.

And thanks to you, the listeners, for joining us.

As a reminder, to view the full program on From Biomarker to Bedside, B7H3-Directed Antibody Drug Conjugates in the Evolving Extensive State Small Cell Long Cancer Treatment Landscape on the Desiree Clinical Education's website, please click on the link in the show notes.

But CDH6 is there in the platinum-resistant ovarian cancer setting as well.

We have so many other targets, B7H4, B7H3, et cetera.

So it's getting to be a crowded area of development, which is great because for our patients, having more opportunities and more potential therapies is only good.

The question then just falls onto us as providers as to trying to figure out and parse out the data of which is the most appropriate.

um however um what's interesting here is they're going after uh gbm with it so this is something that has not worked super well in the past for for solid tumors there's a couple different people that are working on this uh you know curagen bio comes to mind um as as kind of one of those early stage preclinical companies that's also working on this um but yeah there's basically three different things here so first of all it is allogeneic that's pretty unique inside of inside of the space allogeneic kind of went through a little bit of a downturn over the last couple of years, but it seems to be kind of on its way back up.

It's going after a very specific target, which is B7H3.

So I guess this is a protein sitting on the surface of many solid tumors and very little on healthy tissue.

It's one of the most contested targets in oncology.

Local regional delivery of IL-13 receptor alpha two, which is, they have one, they have one here too.

T-Maximum's got their anti IL-13 receptor.

This is a huge one in glioblastoma as well as EGFR V2, as well as B7H3.

I've never heard of M2O2O before.

There are other alpha folate receptor ADCs that we're also evaluating, Torvusam, Rina-S, Sof-M, as all potential options to further exploit the alpha folate receptor protein on cells.

Cadherin-6, HER2, TROP2, B7H3, B7H4, and CloudM6 are also other targets that we're looking at.

There's also many, many more under development.

Most of these drugs have a topo-1 isomerase as the payload, which limits their use because there's really not much data yet on payload after payload using the same payload.

So there are three or four targets out there.

They include DLL3, B7H3, SES6.

Again, proteins on the surface of the tumor cell, and then you have the antibody recognize the tumor cell that way, And then there are molecules of chemotherapy tethered to the antibody by a linker.

And when the antibody touches the tumor cell, it's actually drawn in to the tumor cell into a lysozyme, which has proteases that cleave that linker and then release the payload, which is the chemotherapy.